AR104884A1 - Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj - Google Patents
Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apjInfo
- Publication number
- AR104884A1 AR104884A1 ARP160101639A ARP160101639A AR104884A1 AR 104884 A1 AR104884 A1 AR 104884A1 AR P160101639 A ARP160101639 A AR P160101639A AR P160101639 A ARP160101639 A AR P160101639A AR 104884 A1 AR104884 A1 AR 104884A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- alkyl
- independently selected
- cr4r4
- case
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- 150000002367 halogens Chemical class 0.000 abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 2
- 229910052794 bromium Inorganic materials 0.000 abstract 2
- 229910052801 chlorine Inorganic materials 0.000 abstract 2
- 229910052731 fluorine Inorganic materials 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 2
- 125000006706 (C3-C6) carbocyclyl group Chemical group 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000004452 carbocyclyl group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 150000001721 carbon Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Compuestos agonistas de APJ, que se pueden usar como medicamentos útiles en el tratamiento de enfermedades cardiovasculares. Reivindicación 1: Un compuesto caracterizado por la fórmula [1], o un estereoisómero, un tautómero o una sal de aquel aceptable desde el punto de vista farmacéutico, en donde: alk es C₁₋₆ alquilo sustituido con 0 - 5 Rᵉ; el anillo A se selecciona independientemente de los compuestos del grupo de fórmula [2]; el anillo B se selecciona independientemente de: los compuestos de fórmula [3], fórmula [4] y heteroarilo de 6 miembros; R¹ se selecciona independientemente de: halógeno, NO₂, -(CH₂)ₙORᵇ, (CH₂)ₙS(O)ₚRᶜ, -(CH₂)ₙC(=O)Rᵇ, -(CH₂)ₙNRᵃRᵃ, -(CH₂)ₙCN, -(CH₂)ₙC(=O)NRᵃRᵃ, -(CH₂)ₙNRᵃC(=O)Rᵇ, -(CH₂)ₙNRᵃC(=O)NRᵃRᵃ, -(CH₂)ₙNRᵃC(=O)ORᵇ, -(CH₂)ₙOC(=O)NRᵃRᵃ, -(CH₂)ₙC(=O)ORᵇ, -(CH₂)ₙS(O)ₚNRᵃRᵃ, (CH₂)ₙNRᵃS(O)ₚNRᵃRᵃ, -(CH₂)ₙNRᵃS(O)ₚRᶜ, C₁₋₄ alquilo sustituido con 0 - 3 Rᵉ, -(CH₂)ₙ-C₃₋₆ carbociclilo sustituido con 0 - 3 Rᵉ y -(CH₂)ₙ-heterociclilo sustituido con 0 - 3 Rᵉ; R² se selecciona independientemente de: C₁₋₅ alquilo sustituido con 0 - 3 Rᵉ; C₁₋₅ alquenilo sustituido con 0 - 3 Rᵉ, y C₁₋₆ cicloalquilo sustituido con 0 - 3 Rᵉ; siempre que cuando R² es C₁₋₅ alquilo, los átomos de carbono, salvo el que está unido directamente al anillo de piridina, se puedan reemplazar por O, N y S; R³ se selecciona independientemente de: (1) -(CR⁴R⁴)ʳC(=O)OC₁₋₄, alquilo sustituido son 0 - 5 Rᵉ, (2) -(CR⁴R⁴)ʳNRᵃRᵃ, (3) -(CR⁴R⁴)ʳC(=O)NRᵃRᵃ, (4) -(CR⁴R⁴)ʳNRᵃC(=O)C₁₋₄ alquilo sustituido son 0 - 5 Rᵉ, (5) -(CR⁴R⁴)ʳNRᵃC(=O)(CR⁴R⁴)ₙOC₁₋₄ alquilo sustituido con 0 - 5 Rᵉ, (6) -(CR⁴R⁴)ʳ-R⁵, (7) -(CR⁴R⁴)ʳ-OR⁵, (8) -(CR⁴R⁴)ʳNRᵃC(=O)(CR⁴R⁴)ₙR⁵ y (9) -(CR⁴R⁴)ʳC(=O)NRᵃ(CR⁴R⁴)ₙR⁵; R⁴ se selecciona, independientemente de cada caso, de: H, halógeno, NRᵃRᵃ, OC₁₋₄ alquilo y C₁₋₄ alquilo; o R⁴ y R⁴, junto con el átomo de carbono al que están unidos, forman C₃₋₆ cicloalquilo sustituido con 0 - 5 Rᵉ; R⁵ se selecciona, independientemente de cada caso, de: -(CH₂)ₙC₃₋₁₀ carbociclo y -(CH₂)ₙ-heterociclo, cada uno sustituido con 0 - 3 R⁶; R⁶ se selecciona independientemente de: H, halógeno, =O, -(CH₂)ₙORᵇ, (CH₂)ₙS(O)ₚRᶜ, -(CH₂)ₙC(=O)Rᵇ, -(CH₂)ₙNRᵃRᵃ, -(CH₂)ₙCN, -(CH₂)ₙC(=O)NRᵃRᵃ, -(CH₂)ₙNRᵃC(=O)Rᵇ, -(CH₂)ₙNRᵃC(=O)NRᵃRᵃ, -(CH₂)ₙNRᵃC(=O)ORᵇ, -(CH₂)ₙOC(=O)NRᵃRᵃ, -(CH₂)ₙC(=O)ORᵇ, -(CH₂)ₙS(O)ₚNRᵃRᵃ, -(CH₂)ₙNRᵃS(O)ₚNRᵃRᵃ, -(CH₂)ₙNRᵃS(O)ₚRᶜ, C₁₋₅ alquilo sustituido con 0 - 3 Rᵉ, (CH₂)ₙ-C₃₋₆ carbociclilo sustituido con 0 - 3 Rᵉ y -(CH₂)ₙ-heterociclilo sustituido con 0 - 3 Rᵉ; Rᵃ, en cada caso, se selecciona independientemente de H, C₁₋₆ alquilo sustituido con 0 - 5 Rᵉ, C₂₋₆ alquenilo sustituido con 0 - 5 Rᵉ, C₂₋₆ alquinilo sustituido con 0 - 5 Rᵉ, -(CH₂)ₙ-C₃₋₁₀carbociclilo sustituido con 0 - 5 Rᵉ y -(CH₂)ₙ-heterociclilo sustituido con 0 - 5 Rᵉ; o Rᵃ y Rᵃ, junto con el átomo de nitrógeno al que están unidos, forman un anillo heterocíclico sustituido con 0 - 5 Rᵉ; Rᵇ, en cada caso, se selecciona independientemente de H, C₁₋₆ alquilo sustituido con 0 - 5 Rᵉ, C₂₋₆ alquenilo sustituido con 0 - 5 Rᵉ, C₂₋₆ alquinilo sustituido con 0 - 5 Rᵉ, -(CH₂)ₙ-C₃₋₁₀ carbociclilo sustituido con 0 - 5 Rᵉ y -(CH₂)ₙ-heterociclilo sustituido con 0 - 5 Rᵉ; Rᶜ, en cada caso, se selecciona independientemente C₁₋₆ alquilo sustituido con 0 - 5 Rᵉ, C₂₋₆ alquenilo sustituido con 0 - 5 Rᵉ, C₂₋₆ alquinilo sustituido con 0 - 5 Rᵉ, C₃₋₆ carbociclilo y heterociclilo; Rᵈ, en cada caso, se selecciona independientemente de H y C₁₋₄ alquilo sustituido con 0 - 5 Rᵉ; Rᵉ, en cada caso, se selecciona independientemente C₁₋₆ alquilo sustituido con 0 - 5 Rᶠ, C₂₋₆ alquenilo, C₂₋₆ alquinilo, -(CH₂)ₙ-C₃₋₆ cicloalquilo, -(CH₂)ₙ-C₄₋₆ heterociclilo, -(CH₂)ₙ-arilo, -(CH₂)ₙ-heteroarilo, F, Cl, Br, CN, NO₂, =O, CO₂H, -(CH₂)ₙORᶠ, S(O)ₚRᶠ, C(=O)NRᶠRᶠ, NRᶠC(=O)ₚRᶠ, S(O)ₚNRᶠRᶠ, NRᶠS(O)ₚRᶠ, NRᶠC(=O)ORᶠ, OC(=O)NRᶠRᶠ y -(CH₂)ₙNRᶠRᶠ; Rᶠ, en cada caso, se selecciona independientemente de H, F, Cl, Br, CN, OH, C₁₋₅ alquilo (de manera óptima, sustituido con halógeno y OH), C₃₋₆ cicloalquilo y fenilo, o Rᶠ y Rᶠ, junto con el átomo de nitrógeno al que están unidos, forman un anillo heterocíclico opcionalmente sustituido con C₁₋₄ alquilo; n se selecciona independientemente de 0, 1, 2 y 3; r se selecciona independientemente de 0, 1, 2 y 3; y p, en cada caso, se selecciona independientemente de 0, 1 y 2.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562170215P | 2015-06-03 | 2015-06-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR104884A1 true AR104884A1 (es) | 2017-08-23 |
Family
ID=56131647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160101639A AR104884A1 (es) | 2015-06-03 | 2016-06-02 | Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj |
Country Status (36)
| Country | Link |
|---|---|
| US (3) | US10011594B2 (es) |
| EP (2) | EP3530660A1 (es) |
| JP (2) | JP6483288B2 (es) |
| KR (1) | KR102066336B1 (es) |
| CN (1) | CN107922401B (es) |
| AR (1) | AR104884A1 (es) |
| AU (1) | AU2016270903B2 (es) |
| CA (1) | CA2988147C (es) |
| CL (1) | CL2017003055A1 (es) |
| CO (1) | CO2017013229A2 (es) |
| CY (1) | CY1121938T1 (es) |
| DK (1) | DK3303330T3 (es) |
| EA (1) | EA034912B1 (es) |
| ES (1) | ES2739526T3 (es) |
| HK (1) | HK1247915B (es) |
| HR (1) | HRP20191327T1 (es) |
| HU (1) | HUE045546T2 (es) |
| IL (1) | IL255951B (es) |
| LT (1) | LT3303330T (es) |
| MA (1) | MA41562B1 (es) |
| ME (1) | ME03474B (es) |
| MX (1) | MX2017014956A (es) |
| MY (1) | MY189453A (es) |
| NZ (1) | NZ738563A (es) |
| PE (1) | PE20180506A1 (es) |
| PH (1) | PH12017502158B1 (es) |
| PL (1) | PL3303330T3 (es) |
| PT (1) | PT3303330T (es) |
| RS (1) | RS59220B1 (es) |
| SI (1) | SI3303330T1 (es) |
| SM (1) | SMT201900427T1 (es) |
| TN (1) | TN2017000503A1 (es) |
| TW (1) | TWI672299B (es) |
| UY (1) | UY36705A (es) |
| WO (1) | WO2016196771A1 (es) |
| ZA (1) | ZA201708191B (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6356364B1 (ja) | 2015-05-20 | 2018-07-11 | アムジエン・インコーポレーテツド | Ａｐｊ受容体のトリアゾールアゴニスト |
| CA2988147C (en) | 2015-06-03 | 2023-06-13 | Bristol-Myers Squibb Company | 4-hydroxy-3-(heteroaryl)pyridine-2-one apj agonists for use in the treatment of cardiovascular disorders |
| KR102707502B1 (ko) | 2015-10-14 | 2024-09-13 | 브리스톨-마이어스 스큅 컴퍼니 | Apj 효능제로서의 2,4-디히드록시-니코틴아미드 |
| CA3007280A1 (en) | 2015-12-04 | 2017-06-08 | Bristol-Myers Squibb Company | Apelin receptor agonists and methods of use |
| CA3008630A1 (en) * | 2015-12-16 | 2017-06-22 | Bristol-Myers Squibb Company | Heteroarylhydroxypyrimidinones as agonists of the apj receptor |
| TWI744301B (zh) | 2016-03-24 | 2021-11-01 | 美商必治妥美雅史谷比公司 | 做為apj促效劑之6-羥基-4-側氧-1,4-二氫嘧啶-5-甲醯胺 |
| EP3452466B1 (en) | 2016-05-03 | 2020-08-12 | Amgen Inc. | Heterocyclic triazole compounds as agonists of the apj receptor |
| WO2017218617A1 (en) * | 2016-06-14 | 2017-12-21 | Bristol-Myers Squibb Company | 4-hydroxy-3-sulfonylpyridin-2(1h)-ones as apj receptor agonists |
| WO2017218633A1 (en) | 2016-06-14 | 2017-12-21 | Bristol-Myers Squibb Company | 6-hydroxy-5-(phenyl/heteroarylsulfonyl)pyrimidin-4(1h)-one as apj agonists |
| ES2820223T3 (es) * | 2016-10-14 | 2021-04-20 | Bristol Myers Squibb Co | Agonistas de APJ de 3-sulfonil-5-aminopiridin-2,4-diol |
| EP3541810B1 (en) | 2016-11-16 | 2020-12-23 | Amgen Inc. | Triazole phenyl compounds as agonists of the apj receptor |
| EP3541792B1 (en) | 2016-11-16 | 2020-12-23 | Amgen Inc. | Triazole furan compounds as agonists of the apj receptor |
| US10689367B2 (en) | 2016-11-16 | 2020-06-23 | Amgen Inc. | Triazole pyridyl compounds as agonists of the APJ receptor |
| WO2018097945A1 (en) | 2016-11-16 | 2018-05-31 | Amgen Inc. | Heteroaryl-substituted triazoles as apj receptor agonists |
| EP3541802B1 (en) | 2016-11-16 | 2025-01-01 | Amgen Inc. | Alkyl substituted triazole compounds as agonists of the apj receptor |
| EP3541804B1 (en) | 2016-11-16 | 2025-01-22 | Amgen Inc. | Cycloalkyl substituted triazole compounds as agonists of the apj receptor |
| US10357493B2 (en) | 2017-03-10 | 2019-07-23 | Selenity Therapeutics (Bermuda), Ltd. | Metalloenzyme inhibitor compounds |
| US11149040B2 (en) | 2017-11-03 | 2021-10-19 | Amgen Inc. | Fused triazole agonists of the APJ receptor |
| EP3788037A1 (en) | 2018-05-01 | 2021-03-10 | Amgen Inc. | Substituted pyrimidinones as agonists of the apj receptor |
| CN109704980B (zh) * | 2019-02-16 | 2022-05-13 | 安徽大学 | 一种(z)-3-氨基-2-(2-氟-3-甲氧基苯基)-2-丁烯酸乙酯的制备方法 |
| CN109704981B (zh) * | 2019-02-16 | 2022-01-28 | 安徽诺全药业有限公司 | 取代合成(z)-3-氨基-2-(2-氟-3-甲氧基苯基)-2-丁烯酸乙酯的方法 |
| CN109734616B (zh) * | 2019-02-16 | 2022-05-13 | 安徽诺全药业有限公司 | 两步法合成(z)-3-氨基-2-(2-氟-3-甲氧基苯基)-2-丁烯酸乙酯的方法 |
| TW202438513A (zh) | 2023-01-03 | 2024-10-01 | 美商百愛及生物醫藥公司 | 用於治療與體重增加相關之疾病或病症之愛帕琳(apelin)受體促效劑及glp-1受體促效劑之組合療法 |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1001159A (en) | 1910-07-25 | 1911-08-22 | Elizabeth Nielsen | Skirt-gage. |
| GB1472257A (en) | 1973-09-10 | 1977-05-04 | Christiaens Sa A | Derivative of 4-hydroxy-5-azacoumarin |
| US4866182A (en) | 1988-02-18 | 1989-09-12 | Merrell Dow Pharmaceuticals Inc. | Cardiotonic alkanoyl and aroyl oxazolones |
| US5338740A (en) | 1993-07-13 | 1994-08-16 | Pfizer Inc. | Angiotensin II receptor antagonists |
| JP3795305B2 (ja) | 1999-07-19 | 2006-07-12 | 田辺製薬株式会社 | 医薬組成物 |
| ATE375340T1 (de) | 2001-02-21 | 2007-10-15 | Nps Pharma Inc | Heteropolycyclische verbindungen und deren verwendung als metabotrope glutamatrezeptorantagonisten |
| MXPA03006597A (es) | 2001-03-28 | 2004-10-15 | Pfizer | Derivados de glutaramida sustituida con n-fenpropilciclopentilo como inhibidores de nep para fsad. |
| US7399759B2 (en) | 2001-09-03 | 2008-07-15 | Takeda Pharmaceutical Company Limited | 1, 3-benzothiazinone derivatives and use thereof |
| JP2005162612A (ja) | 2002-01-09 | 2005-06-23 | Ajinomoto Co Inc | アシルスルホンアミド誘導体 |
| JP2005170790A (ja) | 2002-01-09 | 2005-06-30 | Ajinomoto Co Inc | Ｎ−アルキルスルフォニル置換アミド誘導体 |
| PT1490064E (pt) * | 2002-02-14 | 2009-12-28 | Pharmacia Corp | Piridinonas substituídas como moduladores de p38 map-quinase |
| US20040147561A1 (en) * | 2002-12-27 | 2004-07-29 | Wenge Zhong | Pyrid-2-one derivatives and methods of use |
| WO2005004818A2 (en) | 2003-07-09 | 2005-01-20 | Imclone Systems Incorporated | Heterocyclic compounds and their use as anticancer agents |
| US20060004001A1 (en) | 2004-02-27 | 2006-01-05 | Merz Pharma Gmbh & Co., Kgaa | Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors |
| PE20060285A1 (es) * | 2004-03-30 | 2006-05-08 | Aventis Pharma Inc | Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp) |
| MXPA06011167A (es) | 2004-04-01 | 2007-01-25 | Eli Lilli And Company | Agentes del receptor h3 de histamina, preparacion y usos terapeuticos. |
| AU2005257999B2 (en) | 2004-06-18 | 2011-12-08 | Millennium Pharmaceuticals, Inc. | Factor Xa inhibitors |
| DE602005014786D1 (de) | 2004-07-26 | 2009-07-16 | Lilly Co Eli | Oxazolderivate als histamin-h3-rezeptor-wirkstoffe, deren herstellung und therapeutische verwendung |
| EP1655283A1 (en) | 2004-11-08 | 2006-05-10 | Evotec OAI AG | 11beta-HSD1 Inhibitors |
| US20090215777A1 (en) * | 2005-05-19 | 2009-08-27 | Astex Therapeutics Ltd. | Pyrimidine Derivatives As HSP90 Inhibitors |
| WO2007023242A1 (en) | 2005-08-24 | 2007-03-01 | Merz Pharma Gmbh & Co. Kgaa | Tetrahydroquinolinones and their use as modulators of metabotropic glutamate receptors |
| MY161884A (en) | 2006-01-23 | 2017-05-15 | Amgen Inc | Aurora kinase modulators and method of use |
| JP2007314516A (ja) | 2006-04-25 | 2007-12-06 | Daiichi Sankyo Co Ltd | ２以上の置換基を有するベンゼン化合物を含有する医薬 |
| AU2007281212B8 (en) | 2006-08-03 | 2013-02-28 | Trustees Of Tufts College | Non-flushing niacin analogues, and methods of use thereof |
| WO2008019090A2 (en) | 2006-08-04 | 2008-02-14 | Praecis Pharmaceuticals Incorporated | Agonists of the sphingosine-1-phosphate receptor |
| EP1894924A1 (en) | 2006-08-29 | 2008-03-05 | Phenex Pharmaceuticals AG | Heterocyclic FXR binding compounds |
| MX2009005550A (es) | 2006-12-01 | 2009-06-05 | Novartis Ag | Inhibidores de fosfatasa de proteina tirosina para la promocion de la hipertrofia cardiaca fisiologica. |
| WO2008116914A1 (en) | 2007-03-28 | 2008-10-02 | Neurosearch A/S | Purinyl derivatives and their use as potassium channel modulators |
| CN102026970B (zh) * | 2007-11-21 | 2013-07-31 | 解码遗传Ehf公司 | 用于治疗肺部和心血管病症的联芳基pde4抑制剂 |
| RU2010135524A (ru) | 2008-01-25 | 2012-02-27 | Торрент Фармасьютикалз Лтд. (In) | Фармацевтические комбинации |
| TW201000107A (en) | 2008-04-09 | 2010-01-01 | Infinity Pharmaceuticals Inc | Inhibitors of fatty acid amide hydrolase |
| CN102047061A (zh) | 2008-05-30 | 2011-05-04 | 福斯特韦勒能源股份公司 | 通过氧化燃料燃烧发电的方法和系统 |
| AU2009267048A1 (en) | 2008-06-30 | 2010-01-07 | Cylene Pharmaceuticals, Inc. | Oxindole compounds |
| EP2351743A4 (en) | 2008-10-27 | 2012-05-09 | Takeda Pharmaceutical | BICYCLIC COMPOUND |
| WO2010053545A2 (en) * | 2008-11-04 | 2010-05-14 | Anchor Therapeutics, Inc. | Apj receptor compounds |
| JP2013505912A (ja) | 2009-09-24 | 2013-02-21 | エフ．ホフマン−ラ ロシュ アーゲー | 複素環式抗ウイルス化合物 |
| KR20120068947A (ko) | 2009-09-24 | 2012-06-27 | 에프. 호프만-라 로슈 아게 | Ｃｒａｃ 조절제로서의 인돌 유도체 |
| WO2011062955A2 (en) | 2009-11-18 | 2011-05-26 | University Of Massachusetts | Compounds for modulating tlr2 |
| WO2011075684A1 (en) | 2009-12-18 | 2011-06-23 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
| CN102241621A (zh) | 2010-05-11 | 2011-11-16 | 江苏恒瑞医药股份有限公司 | 5,5-双取代-2-亚氨基吡咯烷类衍生物、其制备方法及其在医药上的应用 |
| CN102906074A (zh) | 2010-05-24 | 2013-01-30 | 东亚荣养株式会社 | 稠合咪唑衍生物 |
| JP5869579B2 (ja) * | 2010-09-24 | 2016-02-24 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 置換オキサジアゾール化合物およびそれらのｓ１ｐ１アゴニストとしての使用 |
| WO2012074022A1 (ja) | 2010-12-01 | 2012-06-07 | 旭硝子株式会社 | イリジウムカチオン錯体および発光組成物 |
| EP2681205B1 (en) | 2011-03-03 | 2016-11-16 | Universität des Saarlandes | Biaryl derivatives as selective 17beta-hydroxysteroid dehydrogenase type 2 inhibitors |
| WO2012142308A1 (en) | 2011-04-13 | 2012-10-18 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
| EP2709609B1 (en) | 2011-05-17 | 2017-10-04 | Shionogi & Co., Ltd. | Heterocyclic compounds |
| US9732051B2 (en) | 2011-12-23 | 2017-08-15 | Basf Se | Isothiazoline compounds for combating invertebrate pests |
| WO2013164769A1 (en) * | 2012-05-02 | 2013-11-07 | Lupin Limited | Substituted pyridine compounds as crac modulators |
| BR112014027133A2 (pt) | 2012-05-09 | 2017-06-27 | Basf Se | compostos, composição agrícola ou veterinária, método para o controle das pragas de invertebrados, material de propagação dos vegetais e método para o tratamento ou proteção de um animal. |
| BR112014030720A8 (pt) | 2012-06-08 | 2021-06-22 | The Us Gov As Represented By The Department Of Veterans Affairs | composto, composição farmacêutica e usos de inibidores de fbx03 |
| EP2866803A1 (en) | 2012-07-02 | 2015-05-06 | Max-Delbrück-Centrum für Molekulare Medizin Berlin-Buch | Psoralen derivatives for preventing or treating heart failure or cardiac hypertrophy |
| CN103570625A (zh) | 2012-07-19 | 2014-02-12 | 南京英派药业有限公司 | N-(3-杂芳基芳基)-4-芳基芳基甲酰胺和类似物作为Hedgehog通路抑制剂及其应用 |
| WO2014031928A2 (en) | 2012-08-24 | 2014-02-27 | Philip Jones | Heterocyclic modulators of hif activity for treatment of disease |
| PT2897939T (pt) * | 2012-09-21 | 2017-05-04 | Sanofi Sa | Derivados de amida do ácido benzoimidazol-carboxílico para tratamento de doenças metabólicas ou cardiovasculares |
| WO2014062938A1 (en) | 2012-10-19 | 2014-04-24 | Bristol-Myers Squibb Company | Rory modulators |
| WO2014144715A1 (en) | 2013-03-15 | 2014-09-18 | Memorial Sloan-Kettering Cancer Center | Hsp90-targeted cardiac imaging and therapy |
| WO2015017305A1 (en) | 2013-07-31 | 2015-02-05 | Merck Sharp & Dohme Corp | Inhibitors of the renal outer medullary potassium channel |
| JP6199197B2 (ja) | 2014-02-07 | 2017-09-20 | 花王株式会社 | ポリオキシアルキレンアルキルエーテルカルボン酸塩の製造方法 |
| JP2017071553A (ja) | 2014-02-25 | 2017-04-13 | 味の素株式会社 | ヘテロ原子−メチレン−ヘテロ環構造を有する新規化合物 |
| MX2016012175A (es) | 2014-03-20 | 2017-01-19 | Bayer Pharma AG | Nuevos compuestos. |
| AU2015274781C1 (en) | 2014-06-10 | 2019-08-08 | Sanford-Burnham Medical Research Institute | Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof |
| JP6356364B1 (ja) | 2015-05-20 | 2018-07-11 | アムジエン・インコーポレーテツド | Ａｐｊ受容体のトリアゾールアゴニスト |
| CA2988147C (en) | 2015-06-03 | 2023-06-13 | Bristol-Myers Squibb Company | 4-hydroxy-3-(heteroaryl)pyridine-2-one apj agonists for use in the treatment of cardiovascular disorders |
| KR101711744B1 (ko) | 2015-07-16 | 2017-03-02 | 경희대학교 산학협력단 | 옥사디아졸 유도체, 이의 제조방법 및 이를 포함하는 전자수송층 |
| KR102707502B1 (ko) | 2015-10-14 | 2024-09-13 | 브리스톨-마이어스 스큅 컴퍼니 | Apj 효능제로서의 2,4-디히드록시-니코틴아미드 |
| WO2017091513A1 (en) | 2015-11-24 | 2017-06-01 | Daiichi Sankyo Company, Limited | Novel azole derivatives as apelin receptor agonist |
| CA3007280A1 (en) | 2015-12-04 | 2017-06-08 | Bristol-Myers Squibb Company | Apelin receptor agonists and methods of use |
| AU2016366310C1 (en) | 2015-12-09 | 2021-09-09 | Research Triangle Institute | Improved apelin receptor (APJ) agonists and uses thereof |
| CA3008630A1 (en) | 2015-12-16 | 2017-06-22 | Bristol-Myers Squibb Company | Heteroarylhydroxypyrimidinones as agonists of the apj receptor |
| TWI744301B (zh) | 2016-03-24 | 2021-11-01 | 美商必治妥美雅史谷比公司 | 做為apj促效劑之6-羥基-4-側氧-1,4-二氫嘧啶-5-甲醯胺 |
| WO2017218617A1 (en) | 2016-06-14 | 2017-12-21 | Bristol-Myers Squibb Company | 4-hydroxy-3-sulfonylpyridin-2(1h)-ones as apj receptor agonists |
| WO2017218633A1 (en) | 2016-06-14 | 2017-12-21 | Bristol-Myers Squibb Company | 6-hydroxy-5-(phenyl/heteroarylsulfonyl)pyrimidin-4(1h)-one as apj agonists |
| ES2820223T3 (es) | 2016-10-14 | 2021-04-20 | Bristol Myers Squibb Co | Agonistas de APJ de 3-sulfonil-5-aminopiridin-2,4-diol |
-
2016
- 2016-06-02 CA CA2988147A patent/CA2988147C/en active Active
- 2016-06-02 PE PE2017002482A patent/PE20180506A1/es unknown
- 2016-06-02 TW TW105117468A patent/TWI672299B/zh active
- 2016-06-02 LT LTEP16729454.5T patent/LT3303330T/lt unknown
- 2016-06-02 AU AU2016270903A patent/AU2016270903B2/en active Active
- 2016-06-02 AR ARP160101639A patent/AR104884A1/es unknown
- 2016-06-02 MY MYPI2017704612A patent/MY189453A/en unknown
- 2016-06-02 EP EP19168724.3A patent/EP3530660A1/en not_active Withdrawn
- 2016-06-02 PT PT16729454T patent/PT3303330T/pt unknown
- 2016-06-02 US US15/171,276 patent/US10011594B2/en active Active
- 2016-06-02 EP EP16729454.5A patent/EP3303330B1/en active Active
- 2016-06-02 KR KR1020177037657A patent/KR102066336B1/ko active IP Right Grant
- 2016-06-02 ES ES16729454T patent/ES2739526T3/es active Active
- 2016-06-02 TN TNP/2017/000503A patent/TN2017000503A1/en unknown
- 2016-06-02 MA MA41562A patent/MA41562B1/fr unknown
- 2016-06-02 DK DK16729454.5T patent/DK3303330T3/da active
- 2016-06-02 UY UY0001036705A patent/UY36705A/es unknown
- 2016-06-02 HU HUE16729454A patent/HUE045546T2/hu unknown
- 2016-06-02 SM SM20190427T patent/SMT201900427T1/it unknown
- 2016-06-02 NZ NZ73856316A patent/NZ738563A/en unknown
- 2016-06-02 PL PL16729454T patent/PL3303330T3/pl unknown
- 2016-06-02 PH PH1/2017/502158A patent/PH12017502158B1/en unknown
- 2016-06-02 CN CN201680045336.7A patent/CN107922401B/zh active Active
- 2016-06-02 RS RSP20190961 patent/RS59220B1/sr unknown
- 2016-06-02 EA EA201792548A patent/EA034912B1/ru not_active IP Right Cessation
- 2016-06-02 ME MEP-2019-211A patent/ME03474B/me unknown
- 2016-06-02 WO PCT/US2016/035482 patent/WO2016196771A1/en active Application Filing
- 2016-06-02 JP JP2017562603A patent/JP6483288B2/ja active Active
- 2016-06-02 MX MX2017014956A patent/MX2017014956A/es unknown
- 2016-06-02 SI SI201630316T patent/SI3303330T1/sl unknown
-
2017
- 2017-11-27 IL IL255951A patent/IL255951B/en active IP Right Grant
- 2017-11-30 CL CL2017003055A patent/CL2017003055A1/es unknown
- 2017-12-01 ZA ZA2017/08191A patent/ZA201708191B/en unknown
- 2017-12-21 CO CONC2017/0013229A patent/CO2017013229A2/es unknown
-
2018
- 2018-05-29 US US15/990,855 patent/US10336739B2/en active Active
- 2018-06-04 HK HK18107278.8A patent/HK1247915B/zh unknown
-
2019
- 2019-02-13 JP JP2019023478A patent/JP2019094345A/ja active Pending
- 2019-05-14 US US16/411,221 patent/US20190263791A1/en not_active Abandoned
- 2019-07-24 HR HRP20191327 patent/HRP20191327T1/hr unknown
- 2019-07-29 CY CY20191100803T patent/CY1121938T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR104884A1 (es) | Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj | |
| AR107061A1 (es) | Heteroarilhidroxipirimidinonas como agonistas del receptor de apj | |
| AR106948A1 (es) | Agonistas del receptor de apelina y método de uso | |
| AR110405A1 (es) | Compuestos | |
| AR107973A1 (es) | 6-hidroxi-4-oxo-1,4-dihidropirimidin-5-carboxamidas como agonista de apj | |
| AR096788A1 (es) | Compuestos tricíclicos de carboxamida como inhibidores potentes de rock | |
| AR099379A1 (es) | Compuestos tricíclicos como agentes antineoplásicos | |
| AR103990A1 (es) | Ureas cíclicas como inhibidoras de rock | |
| AR103064A1 (es) | Compuestos moduladores de fxr (nr1h4) | |
| AR104176A1 (es) | Inhibidores de ido (indolamina-2,3-dioxigenasa) | |
| AR092349A1 (es) | Imidazotriazincarbonitrilos utiles como inhibidores de quinasa | |
| AR102177A1 (es) | Compuestos de heteroarilo como inhibidores de btk y usos de los mismos | |
| AR100645A1 (es) | Derivados de pirazolo-pirimidina | |
| AR117617A1 (es) | Compuestos de sulfonilurea como inhibidores de la actividad de interleuquina 1 | |
| AR088829A1 (es) | DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
| AR097082A1 (es) | Compuestos terapéuticamente activos y sus métodos de uso | |
| AR103232A1 (es) | ANTAGONISTAS DE TGFbR | |
| AR090557A1 (es) | DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2 | |
| AR099789A1 (es) | Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina | |
| AR107321A1 (es) | Compuestos antiproliferativos, y sus composiciones farmacéuticas y usos | |
| AR101132A1 (es) | Derivados de pirazina agonistas del gpr40 para el tratamiento de la diabetes tipo ii | |
| AR101589A1 (es) | Derivados de iminonitrilo | |
| AR119376A1 (es) | Compuestos heterocíclicos | |
| AR100439A1 (es) | Derivados de carboxamida | |
| AR102825A1 (es) | Derivados heterocíclicos de amida activos como plaguicidas con sustituyentes que contienen azufre |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |